Dr.EndoEP said:

The shortage clause is the answer to the second question and it is a subtraction rather than an addition.

That holds for the injectable. The oral formulation has different absorption behaviour and the dose numbers are not interchangeable, which is worth saying out loud because people quote them as if they were.

Correct me if the detail matters more than I have assumed.

labquiet_amy said:

Steady state is the thing most people miss.

Thank you — that is the clearest version of this I have read, and I have read a lot of them.

Dr.EndoEP said:

The shortage clause is the answer to the second question and it is a subtraction rather than an addition.

I will push back on the "any working dose is fine" framing. The maintenance evidence sits overwhelmingly at the top studied dose, and the extension data shows regain tracking dose reduction rather than tracking stopping. Holding low is reasonable; pretending it is evidentially equivalent is not.

Adding the numbers, since they settle part of this. Two things anyone can check: a state licence number for a 503A, and an FDA outsourcing-facility registration for a 503B. Both are publicly searchable, and a pharmacy unwilling to give you either has answered the question.

Moderator note: two posts asking for a source have been merged into one. Please search the thread before asking again.